Join
Live feed
·
PRReleasevia Quantisnow
CervoMed Inc. logo

CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit

ByQuantisnow·Wall Street's wire, on your screen.
CRVO· CervoMed Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CRVO (CervoMed Inc.) and more on Quantisnow.